Monopar Therapeutics Inc. (MNPR), Thursday announced positive early data from its ongoing open-label MNPR-101-Zr Phase 1 trial, confirming the compound's tumor-targeting ability in humans.
The study showcased that MNPR-101, a humanized monoclonal antibody, targets cancers expressing the urokinase plasminogen activator receptor such as breast, colorectal, bladder, ovarian, gastric, and pancreatic cancers.
Moreover, the biotechnology company has received a clearance in Australia to commence an MNPR-101-Lu Phase 1 therapeutic clinical trial, which is set to launch in the fourth quarter.
Currently, Monopar's stock is surging 65.38 percent, to $3.98 over the previous close of $2.40 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.